Citation: Xue Zheng, Jizhen Xie, Xing Zhang, Weiting Sun, Heyang Zhao, Yantuan Li, Cheng Wang. An overview of polymeric nanomicelles in clinical trials and on the market[J]. Chinese Chemical Letters, ;2021, 32(1): 243-257. doi: 10.1016/j.cclet.2020.11.029 shu

An overview of polymeric nanomicelles in clinical trials and on the market

Xue Zheng ^a ,
Jizhen Xie ^c ,
Xing Zhang ^a ,
Weiting Sun ^a ,
Heyang Zhao ^a ,
Yantuan Li ^{a, b, *,} ,
Cheng Wang ^{a, b, *,}

a.
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
b.
Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China
c.
Shandong Center for Food and Drug Evaluation and Certification, Ji'nan 250013, China

yantuanli@ouc.edu.cn

cheng13980029671@163.com

Received Date: 28 August 2020
Revised Date: 12 November 2020
Accepted Date: 12 November 2020
Available Online: 20 November 2020

Figures(16)

Polymeric nanomedicine is a promising and rapidly evolving field. Among the different polymeric carriers, polymeric micelle (PM) with nanoscale size exhibit potent physical and biological advantages including excellent solubility and pharmacokinetics, enhanced efficacy and lower toxicity. PM has garnered increasing interest in research and in the clinic. This review will highlight the clinical outcomes of several PM-based formulations, and further summarized their preparation methods, strengths and challenges.
- Polymeric micelles,
- Drug delivery,
- Preparation,
- Clinical application,
- Challenges
1. [1]
  J.N. Meng, V. Agrahari, I. Youm, J. Neuroimmune Pharmacol. 12 (2016) 84-98.
2. [2]
  D. Peer, J.M. Karp, S. Hong, et al., Nat. Nanotechnol. 2 (2007) 751-760. doi: 10.1038/nnano.2007.387
3. [3]
  A.C. Anselmo, S. Mitragotri, Bioeng. Transl. Med. 1 (2016) 10-29. doi: 10.1002/btm2.10003
4. [4]
  C.I. Ochubiojo, M.E. Ibanga, S. Ifianyi, Nanotechnology in drug delivery, in: A. D. Sezer (Ed.), Recent Advances in Novel Drug Carrier Systems, Intech, Croatia, 2012.
5. [5]
  V. Agrahari, V. Agrahari, Drug Discov. Today 23 (2018) 974-991. doi: 10.1016/j.drudis.2018.01.047
6. [6]
  V. Sainz, J. Conniot, A.I. Matos, et al., Biochem. Biophys. Res. Commun. 468 (2015) 504-510. doi: 10.1016/j.bbrc.2015.08.023
7. [7]
  S. Hassan, G. Prakash, A.B. Ozturk, et al., Nano Today 15 (2017) 91-106. doi: 10.1016/j.nantod.2017.06.008
8. [8]
  A. Pandit, D.I. Zeugolis, Nanomedicine: N. B. M. 11 (2016) 985-987. doi: 10.2217/nnm.16.42
9. [9]
  J.H. Xie, Y. Lu, B.Q. Yu, et al., Chin. Chem. Lett. 31 (2020) 1173-1177. doi: 10.1016/j.cclet.2019.10.030
10. [10]
  P. Srikanth, R. Narayana, S.R. Wasim, et al., Adv. Pharm. 3 (2013) 51-58.
11. [11]
  Y. Wang, X.Q. Liang, R.S. Tong, et al., J. Biomed. Nanotechnol. 14 (2018) 1695-1704. doi: 10.1166/jbn.2018.2626
12. [12]
  Q.Q. Hu, L. Bai, Z.J. Zhu, Chin. Chem. Lett. 31 (2020) 915-918. doi: 10.1016/j.cclet.2020.01.008
13. [13]
  Y. Zhou, A.P. Fang, F.Z. Wang, et al., Chin. Chem. Lett. 31 (2020) 494-500. doi: 10.1016/j.cclet.2019.04.048
14. [14]
  X. Zhang, X. Ren, J. Tang, et al., Drug Deliv. 27 (2020) 825-835. doi: 10.1080/10717544.2020.1770373
15. [15]
  Y. Liang, Q.Q. Huo, W. Lu, et al., J. Biomed. Nanotechnol. 14 (2018) 1308-1316. doi: 10.1166/jbn.2018.2585
16. [16]
  Y. Qu, B. Chu, X. Wei, et al., J. Control. Release 296 (2019) 93-106. doi: 10.1016/j.jconrel.2019.01.016
17. [17]
  S.S. Kulthe, Y.M. Choudhari, N.N. Inamdar, et al., Des. Monomers Polym. 15 (2012) 465-521. doi: 10.1080/1385772X.2012.688328
18. [18]
  M. Talelli, M. Barz, C.J.F. Rijcken, et al., Nano Today 10 (2015) 93-117. doi: 10.1016/j.nantod.2015.01.005
19. [19]
  Y. Wang, X.X. Wang, J. Zhang, et al., Chin. Chem. Lett. 30 (2019) 885-888. doi: 10.1016/j.cclet.2019.02.018
20. [20]
  C.L. Zhu, S. Gong, J.S. Ding, et al., Acta Pharm. Sin. B 9 (2019) 107-117. doi: 10.1016/j.apsb.2018.09.004
21. [21]
  M. Cagel, F.C. Tesan, E. Bernabeu, et al., Eur. J. Pharm. Biopharm. 113 (2017) 211-228. doi: 10.1016/j.ejpb.2016.12.019
22. [22]
  Z. Zhang, Q. Sun, J. Zhong, et al., J. Biomed. Nanotechnol. 10 (2014) 216-226. doi: 10.1166/jbn.2014.1729
23. [23]
  K. Miyata, N. Nishiyama, K. Kataoka, Chem. Soc. Rev. 41 (2012) 2562-2574. doi: 10.1039/C1CS15258K
24. [24]
  N. Nishiyama, K. Kataoka, Adv. Polym. Sci. 193 (2015) 67-101.
25. [25]
  X. Xu, W. Ho, X. Zhang, et al., Trends Mol. Med. 21 (2015) 223-232. doi: 10.1016/j.molmed.2015.01.001
26. [26]
  J.M. Caster, A.N. Patel, T. Zhang, A. Wang, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 9 (2017) 1-18.
27. [27]
  H. Havel, G. Finch, P. Strode, et al., AAPS J. 18 (2016) 1-6. doi: 10.1208/s12248-015-9820-y
28. [28]
  C.L. Ventola, Dermatol. Ther. 37 (2012) 631-639.
29. [29]
  D. Bobo, K.J. Robinson, J. Islam, et al., Pharm. Res. 33 (2016) 2373-2387. doi: 10.1007/s11095-016-1958-5
30. [30]
  E.W. Party, C.F.R.F. Consultation, Stat. Med. 25 (2010) 1639-1645.
31. [31]
  A.J.M. Ferreri, T. Calimeri, G.M. Conte, et al., Blood 134 (2019) 252-262.
32. [32]
  C. Khanna, M. Rosenberg, D.M. Vail, J. Vet. Intern. Med. 29 (2015) 1006-1012. doi: 10.1111/jvim.12596
33. [33]
  Z.Y. Fan, C. Chen, X.Y. Pang, et al., PLoS One 10 (2015) e0120129. doi: 10.1371/journal.pone.0120129
34. [34]
  E. Miele, G.P. Spinelli, F. Tomao, Int. J. Nanomed. Nanosurg. 99 (2009) 99-105.
35. [35]
  C.P. Yang, S. Horwitz, Int. J. Mol. Sci. 18 (2017) 1733. doi: 10.3390/ijms18081733
36. [36]
  S.C. Kim, D.W. Kim, Y.H. Shim, et al., J. Control. Release 72 (2001) 191-202. doi: 10.1016/S0168-3659(01)00275-9
37. [37]
  K.S. Lee, H.C. Chung, S.A. Im, et al., Breast Cancer Res. Tr. 108 (2007) 217-222.
38. [38]
  D.W. Kim, S.Y. Kim, H.K. Kim, et al., Ann. Oncol. 18 (2007) 2009-2014. doi: 10.1093/annonc/mdm374
39. [39]
  T.Y. Kim, J.Y. Chung, Clin. Cancer Res. 10 (2004) 3708-3716. doi: 10.1158/1078-0432.CCR-03-0655
40. [40]
  H.S. Kim, J.Y. Lee, S.H. Lim, et al., J. Thorac. Oncol. 10 (2015) 762-768. doi: 10.1097/JTO.0000000000000489
41. [41]
  J.L. Lee, J.H. Ahn, S.H. Park, et al., Invest. New Drugs 30 (2012) 1984-1990. doi: 10.1007/s10637-011-9757-7
42. [42]
  M.W. Saif, N.A. Podoltsev, M.S. Rubin, et al., Cancer Invest. 28 (2010) 186-194.
43. [43]
  S. Margaritora, A. Cesario, G. Cusumano, et al., Ann. Thorac. Surg. 89 (2010) 245-252. doi: 10.1016/j.athoracsur.2009.08.074
44. [44]
  G.L. Lemma, J.W. Lee, S.C. Aisner, et al., J. Clin. Oncol. 29 (2011) 2060-2065. doi: 10.1200/JCO.2010.32.9607
45. [45]
  H.K. Ahn, S.J. Sym, et al., Cancer Chemoth. Pharm. 74 (2014) 277-282. doi: 10.1007/s00280-014-2498-5
46. [46]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=GenexolPM&cntry=&state=&city=&dist=.
47. [47]
  A. Saklani, S. Kutty, Drug Discov. Today 13 (2008) 161-171. doi: 10.1016/j.drudis.2007.10.010
48. [48]
  Y. Zhao, Z.F. Chang, R. Li, et al., Am. J. Transl. Res. 8 (2016) 5044-5051.
49. [49]
  S. Jayashree, K. Nirekshana, G. Guha, D. Bhakta-Guha, Biomed. Pharmacother. 102 (2018) 894-911. doi: 10.1016/j.biopha.2018.03.123
50. [50]
  X. Zhang, H.M. Burt, D.V. Hoff, et al., Cancer Chemoth. Pharm. 40 (1997) 81-86. doi: 10.1007/s002800050630
51. [51]
  X. Yin, X. Cao, J. Li, et al., AAPS PharmSciTech 20 (2019) 629-638.
52. [52]
  A. Ehrlich, S. Booher, Y. Becerra, et al., J. Am. Acad. Dermatol. 50 (2004) 533-540. doi: 10.1016/j.jaad.2003.09.018
53. [53]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=Paxceed&cntry=&state=&city=&dist=.
54. [54]
  S. Emoto, H. Yamaguchi, J. Kishikawa, et al., Cancer Sci. 103 (2012) 1304-1310. doi: 10.1111/j.1349-7006.2012.02274.x
55. [55]
  I. Nakamura, E. Ichimura, R. Goda, et al., Int. J. Nanomedicine 12 (2017) 1293-1304. doi: 10.2147/IJN.S114356
56. [56]
  T. Hamaguchi, Y. Matsumura, M. Suzuki, et al., Brit. J. Cancer 92 (2005) 1240-1246. doi: 10.1038/sj.bjc.6602479
57. [57]
  T. Negishi, F. Koizumi, H. Uchino, et al., Brit. J. Cancer 95 (2006) 601-606. doi: 10.1038/sj.bjc.6603311
58. [58]
  K. Kato, K. Chin, T. Yoshikawa, et al., Invest. New Drugs 30 (2011) 1621-1627.
59. [59]
  H. Mukai, K. Kato, T. Esaki, et al., Invest. New Drugs 34 (2016) 750-759. doi: 10.1007/s10637-016-0381-4
60. [60]
  T. Hamaguchi, K. Kato, H. Yasui, et al., Br. J. Cancer 97 (2007) 170-176. doi: 10.1038/sj.bjc.6603855
61. [61]
  Y. Fujiwara, H. Mukai, T. Saeki, et al., Brit. J. Cancer 120 (2019) 475-482. doi: 10.1038/s41416-019-0391-z
62. [62]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=NK105&cntry=&state=&city=&dist=.
63. [63]
  H. von Euler, P. Rivera, H. Nyman, et al., Vet. Comp. Oncol. 11 (2013) 243-255. doi: 10.1111/j.1476-5829.2011.00314.x
64. [64]
  S. Hassan, S. Dhar, M. Sandström, et al., Cancer Chemoth. Pharm. 55 (2005) 47-54. doi: 10.1007/s00280-004-0855-5
65. [65]
  P. Rivera, N. Åkerlund-Denneberg, K. Bergvall, et al., J. Small Anim. Pract. 54 (2013) 20-27. doi: 10.1111/j.1748-5827.2012.01304.x
66. [66]
  D.M. Vail, H. von Euler, A.W. Rusk, et al., J. Vet. Intern. Med. 26 (2012) 598-607. doi: 10.1111/j.1939-1676.2012.00897.x
67. [67]
  B.G.H. Choudhury, M. Pandey, et al., Int. J. Pharm. 529 (2018) 506-522.
68. [68]
  E.T. Oh, C.W. Kim, S.J. Kim, et al., Sci. Rep. -UK. 6 (2016) 1-37. doi: 10.1038/s41598-016-0001-8
69. [69]
  J.J.M.A. Hendrikx, J.S. Lagas, J.Y. Song, et al., Int. J. Cancer 138 (2016) 758-769. doi: 10.1002/ijc.29812
70. [70]
  S.Y. Song, K. Kim, S.Y. Jeong, Oncotarget 7 (2016) 77348-77357. doi: 10.18632/oncotarget.12668
71. [71]
  Y.M. Yin, F.D. Cui, C.F. Mu, et al., J. Control. Release 140 (2009) 86-94. doi: 10.1016/j.jconrel.2009.08.015
72. [72]
  G. Palma, C. Conte, A. Barbieri, et al., Int. J. Pharmaceut. 473 (2014) 55-63. doi: 10.1016/j.ijpharm.2014.06.058
73. [73]
  D.D. Von Hoff, M.M. Mita, R.K. Ramanathan, et al., Clin. Cancer Res. 22 (2016) 3157-3163. doi: 10.1158/1078-0432.CCR-15-2548
74. [74]
  J. Hrkach, D. Von Hoff, M.M. Ali, et al., Sci. Transl. Med. 4 (2012) 128-139.
75. [75]
  K.A. Autio, R. Dreicer, J. Anderson, et al., JAMA Oncol. 4 (2018) 1344-1351. doi: 10.1001/jamaoncol.2018.2168
76. [76]
  H. Ledford, Biotechnology 533 (2016) 304-305.
77. [77]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=BIND-014&cntry=&state=&city=&dist=.
78. [78]
  S.W. Lee, M.H. Yun, S.W. Jeong, et al., J. Control. Release 155 (2011) 262-271. doi: 10.1016/j.jconrel.2011.06.012
79. [79]
  V.Q. Do, K.H. Park, J.M. Park, M.Y. Lee, Toxicol. Res. 35 (2019) 201-207. doi: 10.5487/TR.2019.35.2.201
80. [80]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=Nanoxel&cntry=&state=&city=&dist=.
81. [81]
  ClinicalTrials. gov database, (2020). https://www.Clinicaltrialsregister.eu/ctr-search/search?query=Docecal.
82. [82]
  X. Duan, C. He, S.J. Kron, W. Lin, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8 (2016) 776-791. doi: 10.1002/wnan.1390
83. [83]
  M. Yokoyama, T. Okano, Y. Sakurai, et al., J. Control. Release 39 (1996) 351-356. doi: 10.1016/0168-3659(95)00165-4
84. [84]
  Y. Mochida, H. Cabral, Y. Miura, et al., ACS Nano 8 (2014) 6724-6738. doi: 10.1021/nn500498t
85. [85]
  H. Uchino, Y. Matsumura, T. Negishi, et al., Brit. J. Cancer 93 (2005) 678-687. doi: 10.1038/sj.bjc.6602772
86. [86]
  N. Nishiyama, S. Okazaki, H. Cabral, et al., Cancer Res. 63 (2013) 8977-8983.
87. [87]
  A. Varela-Moreira, Y. Shi, M.H.A.M. Fens, et al., Mater. Chem. Front. 1 (2017) 1485-1501. doi: 10.1039/C6QM00289G
88. [88]
  R. Plummer, R.H. Wilson, H. Calvert, et al., Brit. J. Cancer 104 (2011) 593-598. doi: 10.1038/bjc.2011.6
89. [89]
  T. Doi, T. Hamaguchi, K. Shitara, et al., Cancer Chemoth. Pharm. 79 (2017) 569-578. doi: 10.1007/s00280-017-3254-4
90. [90]
  V. Subbiah, J.E. Grilley-Olson, A.J. Combest, et al., Clin. Cancer Res. 24 (2018) 43-51. doi: 10.1158/1078-0432.CCR-17-1114
91. [91]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=NC6004&cntry=&state=&city=&dist=.
92. [92]
  J. Cassidy, J.L. Misset, Semin. Oncol. 29 (2002) 11-20. doi: 10.1053/sonc.2002.35524
93. [93]
  H. Cabral, N. Nishiyama, S. Okazaki, et al., J. Control. Release 101 (2005) 223-232. doi: 10.1016/j.jconrel.2004.08.022
94. [94]
  R.H. Wilson, T. Lehky, R.R. Thomas, et al., J. Clin. Oncol. 20 (2002) 1767-1774. doi: 10.1200/JCO.2002.07.056
95. [95]
  L. Kelland, Nat. Rev. Cancer 7 (2007) 573-584. doi: 10.1038/nrc2167
96. [96]
  H. Cabral, K. Kataoka, J. Control. Release 121 (2007) 146-155. doi: 10.1016/j.jconrel.2007.05.024
97. [97]
  A.X. Zhu, L.S. Blaszkowsky, D.P. Ryan, et al., J. Clin. Oncol. 24 (2006) 1898-1903. doi: 10.1200/JCO.2005.04.9130
98. [98]
  H.J. Schmoll, T. Cartwright, J. Tabernero, et al., J. Clin. Oncol. 26 (2007) 102-109. doi: 10.1200/JCO.2006.08.1075
99. [99]
  J. Cassidy, S. Clarke, E. Díaz-Rubio, et al., J. Clin. Oncol. 26 (2008) 2006-2012. doi: 10.1200/JCO.2007.14.9898
100. [100]
  M. Ducreux, E. Mitry, M. Ould-Kaci, et al., Ann. Oncol. 15 (2004) 467-473. doi: 10.1093/annonc/mdh098
101. [101]
  C. Louvet, R. Labianca, P. Hammel, et al., J. Clin. Oncol. 23 (2005) 3509-3516. doi: 10.1200/JCO.2005.06.023
102. [102]
  C. Louvet, T. André, G. Lledo, et al., J. Clin. Oncol. 20 (2002) 1512-1518. doi: 10.1200/JCO.2002.20.6.1512
103. [103]
  S.R. Alberts, W.L. Horvath, W.C. Sternfeld, et al., J. Clin. Oncol. 23 (2005) 9243-9249. doi: 10.1200/JCO.2005.07.740
104. [104]
  N.I. Khushalani, C.G. Leichman, G. Proulx, et al., J. Clin. Oncol. 20 (2002) 2844-2850. doi: 10.1200/JCO.2002.12.032
105. [105]
  F. Lordick, B. Luber, S. Lorenzen, et al., Br. J. Cancer 102 (2010) 500-505. doi: 10.1038/sj.bjc.6605521
106. [106]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=NC4016&cntry=&state=&city=&dist=.
107. [107]
  C. Annabelle, C. Nina, T. Nouritza, et al., Oncotarget 9 (2018) 14539-14551. doi: 10.18632/oncotarget.24465
108. [108]
  L.A.A. Gilliam, D.K. St. Clair, Antioxid. Redox Sign. 15 (2011) 2543-2563. doi: 10.1089/ars.2011.3965
109. [109]
  G. Stefania, D.A. Antonella, B. Liberato, et al., Oxid. Med. Cell. Longev. 75 (2018) 1-15.
110. [110]
  C. Maximiliano, G. Estefania, B. Ezequiel, et al., Drug Discov. Today 22 (2017) 270-281. doi: 10.1016/j.drudis.2016.11.005
111. [111]
  F. Arcamone, G. Cassinelli, G. Fantini, et al., Biotechnol. Bioeng. 67 (2000) 704-713. doi: 10.1002/(SICI)1097-0290(20000320)67:6<704::AID-BIT8>3.0.CO;2-L
112. [112]
  M.A. Mitry, J.G. Edwards, Int. J. Cardiol. Heart Vasc. 10 (2015) 17-24.
113. [113]
  D. Ren, M. Dalmau, A. Randall, et al., Adv. Funct. Mater. 22 (2012) 3170-3180. doi: 10.1002/adfm.201200052
114. [114]
  T. Nakanishi, S. Fukushima, K. Okamoto, et al., J. Control. Release 74 (2001) 295-302. doi: 10.1016/S0168-3659(01)00341-8
115. [115]
  Y. Matsumura, T. Hamaguchi, T. Ura, et al., Brit. J. Cancer 91 (2004) 1775-1781. doi: 10.1038/sj.bjc.6602204
116. [116]
  A.V. Kabanov, E.V. Batrakova, V.Y. Alakhov, Adv. Drug Deliv. Rev. 54 (2002) 759-779. doi: 10.1016/S0169-409X(02)00047-9
117. [117]
  S. Danson, D. Ferry, V. Alakhov, et al., Brit. J. Cancer 90 (2004) 2085-2091. doi: 10.1038/sj.bjc.6601856
118. [118]
  J.W. Valle, A. Armstrong, C. Newman, et al., Invest. New Drugs 29 (2010) 1029-1037.
119. [119]
  A. Takahashi, Y. Yamamoto, M. Yasunaga, et al., Cancer Sci. 104 (2013) 920-925. doi: 10.1111/cas.12153
120. [120]
  Y. Matsumura, J. Clin. Oncol. 44 (2014) 515-525.
121. [121]
  X.F. Wang, Z.F. Zhao, M.H. Chen, et al., Mol. Med. Rep. 12 (2015) 5917-5923. doi: 10.3892/mmr.2015.4220
122. [122]
  L.S. Tarpgaard, C. Qvortrup, S.B. Nygard, et al., BMC Cancer 16 (2016) 91. doi: 10.1186/s12885-016-2124-5
123. [123]
  H. Mukai, T. Kogawa, N. Matsubara, et al., Invest. New Drugs 35 (2017) 307-314. doi: 10.1007/s10637-016-0422-z
124. [124]
  M. Harada, I. Bobe, H. Saito, et al., Cancer Sci. 102 (2011) 192-199. doi: 10.1111/j.1349-7006.2010.01745.x
125. [125]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=+NC6300&cntry=&state=&city=&dist=.
126. [126]
  C. Chaves, M. Taghi, M.C. Menet, et al., Pharmaceutics 12 (2020) 399-417. doi: 10.3390/pharmaceutics12050399
127. [127]
  M. Sumitomo, F. Koizumi, T. Asano, et al., Cancer Res. 68 (2008) 1631-1635. doi: 10.1158/0008-5472.CAN-07-6532
128. [128]
  Y. Matsumura, Adv. Drug Deliv. Rev. 63 (2011) 184-192. doi: 10.1016/j.addr.2010.05.008
129. [129]
  F.F. Han, C.L. Guo, D. Yu, et al., Cancer Chemoth. Pharm. 73 (2014) 779-788. doi: 10.1007/s00280-014-2405-0
130. [130]
  J. Gao, J. Zhou, Y. Li, et al., Medical Oncol. 30 (2013) 1-6.
131. [131]
  J.A. Zhang, T. Xuan, M. Parmar, et al., Int. J. Pharm. 270 (2004) 93-107. doi: 10.1016/j.ijpharm.2003.10.015
132. [132]
  R. Zhang, R. Saito, Y. Mano, et al., Drug Deliv. 23 (2016) 2780-2786. doi: 10.3109/10717544.2015.1081994
133. [133]
  H.A. Burris, J.R. Infante, F.A. Greco, et al., Cancer Chemother. Pharmacol. 77 (2016) 1079-1086. doi: 10.1007/s00280-016-2986-x
134. [134]
  T. Hamaguchi, T. Doi, T. Eguchi-Nakajima, et al., Clin. Cancer Res. 16 (2010) 5058-5066. doi: 10.1158/1078-0432.CCR-10-0387
135. [135]
  T. Hamaguchi, A. Tsuji, K. Yamaguchi, et al., Cancer Chemother. Pharm. 82 (2018) 1021-1029. doi: 10.1007/s00280-018-3693-6
136. [136]
  T. Nagano, M. Yasunaga, K. Goto, et al., Clin. Cancer Res. 15 (2009) 4348-4355. doi: 10.1158/1078-0432.CCR-08-3334
137. [137]
  T.E. Nakajima, M. Yasunaga, Y. Kano, et al., Int. J. Cancer 122 (2008) 2148-2153. doi: 10.1002/ijc.23381
138. [138]
  ClinicalTrials. gov database, (2020). https://www.clinicaltrials.gov/ct2/results?cond=&term=NK012&cntry=&state=&city=&dist=.
139. [139]
  S. Sindhwani, A.M. Syed, J. Ngai, et al., Nat. Mater. 19 (2020) 566-575. doi: 10.1038/s41563-019-0566-2
140. [140]
  S.M. Kim, P.H. Faix, J.E. Schnitzer, J. Control. Release 267 (2017) 15-30. doi: 10.1016/j.jconrel.2017.09.016
141. [141]
  R. Daniel, T. Wei, Nat. Commun. 9 (2018) 1410. doi: 10.1038/s41467-018-03705-y
142. [142]
  A. Nel, E. Ruoslahti, H. Meng, ACS Nano 11 (2017) 9567-9569. doi: 10.1021/acsnano.7b07214
143. [143]
  J. Liu, X.X. Ai, H.P. Zhang, et al., J. Biomed. Nanotechnol. 15 (2019) 373-381. doi: 10.1166/jbn.2019.2693
144. [144]
  Y. Qu, B.Y. Chu, K. Shi, et al., J. Biomed. Nanotechnol. 13 (2017) 1598-1618. doi: 10.1166/jbn.2017.2475
145. [145]
  L.M.K. Ma, S. Andrew, ACS Nano 7 (2013) 9518-9525. doi: 10.1021/nn405674m
146. [146]
  E.J. Feldman, J.E. Lancet, J.E. Kolitz, et al., J. Clin. Oncol. 29 (2011) 979-985. doi: 10.1200/JCO.2010.30.5961
147. [147]
  O. Trédan, C.M. Galmarini, P. Krupa, et al., J. Natl. Cancer Inst. 99 (2007) 1441-1454. doi: 10.1093/jnci/djm135
148. [148]
  N. Vasan, J. Baselga, D.M. Hyman, Nature 575 (2019) 299-309. doi: 10.1038/s41586-019-1730-1
149. [149]
  W. Mu, Q. Chu, Y. Liu, N. Zhang, Nano-Micro Lett. 142 (2020).
150. [150]
  Z. Yu, J.F. Guo, M.G. Hu, et al., ACS Nano 14 (2020) 4816-4828. doi: 10.1021/acsnano.0c00708
151. [151]
  N. Casares, M.O. Pequignot, A. Tesniere, et al., J. Exp. Med. 202 (2005) 1691-1701. doi: 10.1084/jem.20050915
152. [152]
  J.M. Llovet, J. Zucman-Rossi, E. Pikarsky, et al., Nat. Rev. Dis. Primers 2 (2016) 16018. doi: 10.1038/nrdp.2016.18
153. [153]
  S. Kim, Y. Shi, J.Y. Kim, et al., Expert Opin. Drug Del. 7 (2010) 49-62. doi: 10.1517/17425240903380446
154. [154]
  N.R. Stillman, M. Kovacevic, I. Balaz, et al., NPJ Comput. Mater. 92 (2020), doi:10.1038/s41524-020-00366-8. doi: 10.1038/s41524-020-00366-8
155. [155]
  C. Fornaguera, M. García-Celma, J. Pers. Med. 7 (2017) 1-11. doi: 10.3390/jpm7010001
156. [156]
  D.V. Bazile, J. Drug Deliv. Sci. Tec. 24 (2014) 12-21. doi: 10.1016/S1773-2247(14)50002-0
157. [157]
  M.L. Etheridge, S.A. Campbell, A.G. Erdman, et al., Nanomedicine 9 (2013) 1-14. doi: 10.1016/j.nano.2012.05.013
158. [158]
  J.H. Grossman, J.D. Clogston, AAPS J. 19 (2017) 92-102. doi: 10.1208/s12248-016-9980-4
159. [159]
  S. Tinkle, S.E. McNeil, S. Mühlebach, et al., Ann. NY. Acad. Sci. 1313 (2014) 35-56. doi: 10.1111/nyas.12403
160. [160]
  I.P. Kaur, V. Kakkar, P.K. Deol, et al., J. Control. Release 193 (2014) 51-62. doi: 10.1016/j.jconrel.2014.06.005
161. [161]
  N. Desai, AAPS J. 14 (2012) 282-295. doi: 10.1208/s12248-012-9339-4
162. [162]
  V. Agrahari, P. Hiremath, Nanomedicine 12 (2017) 819-823. doi: 10.2217/nnm-2017-0039
163. [163]
  J.I. Hare, T. Lammers, M.B. Ashford, et al., Adv. Drug Deliv. Rev. 108 (2017) 25-38. doi: 10.1016/j.addr.2016.04.025
1. [1]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420
2. [2]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
3. [3]
  Jia Fu , Shilong Zhang , Lirong Liang , Chunyu Du , Zhenqiang Ye , Guangming Chen . PEDOT-based thermoelectric composites: Preparation, mechanism and applications. Chinese Chemical Letters, 2024, 35(9): 109804-. doi: 10.1016/j.cclet.2024.109804
4. [4]
  Jiaqi Huang , Renjiang Kong , Yanmei Li , Ni Yan , Yeyang Wu , Ziwen Qiu , Zhenming Lu , Xiaona Rao , Shiying Li , Hong Cheng . Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chinese Chemical Letters, 2024, 35(8): 109254-. doi: 10.1016/j.cclet.2023.109254
5. [5]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
6. [6]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511
7. [7]
  Hao Deng , Yuxin Hui , Chao Zhang , Qi Zhou , Qiang Li , Hao Du , Derek Hao , Guoxiang Yang , Qi Wang . MXene−derived quantum dots based photocatalysts: Synthesis, application, prospects, and challenges. Chinese Chemical Letters, 2024, 35(6): 109078-. doi: 10.1016/j.cclet.2023.109078
8. [8]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335
9. [9]
  Yating Zheng , Yulan Huang , Jing Luo , Xuqi Peng , Xiran Gui , Gang Liu , Yang Zhang . Supercritical fluid technology: A game-changer for biomacromolecular nanomedicine preparation and biomedical application. Chinese Chemical Letters, 2024, 35(7): 109169-. doi: 10.1016/j.cclet.2023.109169
10. [10]
  Yu Qin , Mingyang Huang , Chenlu Huang , Hannah L. Perry , Linhua Zhang , Dunwan Zhu . O₂-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in melanoma. Chinese Chemical Letters, 2024, 35(7): 109171-. doi: 10.1016/j.cclet.2023.109171
11. [11]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
12. [12]
  Yanqi Wu , Yuhong Guan , Peilin Huang , Hui Chen , Liping Bai , Zhihong Jiang . Preparation of norovirus GII loop mediated isothermal amplification freeze-drying microsphere reagents and its application in an on-site integrated rapid detection platform. Chinese Chemical Letters, 2024, 35(9): 109308-. doi: 10.1016/j.cclet.2023.109308
13. [13]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
14. [14]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
15. [15]
  Xiaoyan Peng , Xuanhao Wu , Fan Yang , Yefei Tian , Mingming Zhang , Hongye Yuan . Gas sensors based on metal-organic frameworks: challenges and opportunities. Chinese Journal of Structural Chemistry, 2024, 43(3): 100251-100251. doi: 10.1016/j.cjsc.2024.100251
16. [16]
  Yue Wang , Caixia Xu , Xingtao Tian , Siyu Wang , Yan Zhao . Challenges and Modification Strategies of High-Voltage Cathode Materials for Li-ion Batteries. Chinese Journal of Structural Chemistry, 2023, 42(10): 100167-100167. doi: 10.1016/j.cjsc.2023.100167
17. [17]
  Feibin Wei , Yongfang Rao , Yu Huang , Wei Wang , Hui Mei . The new challenges for the development of NH₃-SCR catalysts under new situation of energy transition in power generation industry. Chinese Chemical Letters, 2024, 35(6): 108931-. doi: 10.1016/j.cclet.2023.108931
18. [18]
  Yulong Liu , Haoran Lu , Tong Yang , Peng Cheng , Xu Han , Wenyan Liang . Catalytic applications of amorphous alloys in wastewater treatment: A review on mechanisms, recent trends, challenges and future directions. Chinese Chemical Letters, 2024, 35(10): 109492-. doi: 10.1016/j.cclet.2024.109492
19. [19]
  Jun LI , Huipeng LI , Hua ZHAO , Qinlong LIU . Preparation and photocatalytic performance of AgNi bimetallic modified polyhedral bismuth vanadate. Chinese Journal of Inorganic Chemistry, 2024, 40(3): 601-612. doi: 10.11862/CJIC.20230401
20. [20]
  Ning LI , Siyu DU , Xueyi WANG , Hui YANG , Tao ZHOU , Zhimin GUAN , Peng FEI , Hongfang MA , Shang JIANG . Preparation and efficient catalysis for olefins epoxidation of a polyoxovanadate-based hybrid. Chinese Journal of Inorganic Chemistry, 2024, 40(4): 799-808. doi: 10.11862/CJIC.20230372

Get Citation

PDF

XML

Metrics

PDF Downloads(67)
Abstract views(2613)
HTML views(526)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142